Cart
sales@molnova.com
PF-06873600
CAS No. 2185857-97-8
PF-06873600 ( PF06873600;PF 06873600 )
Catalog No. M13486 CAS No. 2185857-97-8
PF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 254 | Get Quote |
|
| 10MG | 403 | Get Quote |
|
| 25MG | 762 | Get Quote |
|
| 50MG | 1017 | Get Quote |
|
| 100MG | 1377 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePF-06873600
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.
-
DescriptionPF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively; demonstrates potential antineoplastic activity, incerease apoptosis and inhibits umor cell proliferation.Breast Cancer Phase 2 Clinical
-
SynonymsPF06873600;PF 06873600
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number2185857-97-8
-
Formula Weight471.52
-
Molecular FormulaC20H27F2N5O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 83.33 mg/mL 176.73 mM
-
SMILESO=C1C(C(F)F)=CC2=CN=C(NC3CCN(S(=O)(C)=O)CC3)N=C2N1[C@H]4[C@](C)(O)CCC4
-
Chemical NamePyrido[2,3-d]pyrimidin-7(8H)-one, 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Ro-3306
Ro-3306 is a potent and selective inhibitor of CDK1, with Kis of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.
-
Ibulocydine
Ibulocydine is the prodrug of CDK inhibitor BMK-Y101, inhibits CDK7 and CDK9 with IC50 of 530 nM and 85 nM in kinase assays, respectively.
-
THZ2
THZ2, an analogue of THZ1 with improved pharmacokinetic features, is a potent, selective CDK7 inhibitor with IC50 of 13.9 nM, displays a 5-fold improved half-life in vivo compared with THZ1.
